Maisa Feghali checked her email last Thursday morning, and got a surprise.

Because she’s particularly interested in pharmacology, she subscribes to the U.S. Food and Drug Administration’s emails about drug safety labeling changes. Many times, none of the inclusions affect her as a maternal fetal medicine (or high-risk) obstetrician at the University of Pittsburgh Medical Center and assistant professor in the department of obstetrics, gynecology and reproductive science at the school.

As she scrolled through that morning’s list, however, she noticed every first-line anxiety and depression medication — a pharmaceutical class known as SSRIs (selective serotonin reuptake inhibitors) — listed: Celexa, Prozac, Lexapro, Paxil and Zoloft, plus an SSRI-containing medication called Symbyax and related drugs such as Effexor XR, Cymbalta and Pristiq.

Then, she clicked the hyperlinks. Each one had the same language added to their labels as of Aug. 18: “Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than two-fold increase in the risk of postpartum hemorrhage.”

Advertise with us

Anxiety disorders affect up to 40 million American adults each year, with women more than twice as likely as men to develop one.

Having at least one major depressive episode also disproportionately affects women.

With over 3.66 million live births in the U.S. last year, there’s plenty of crossover, with 6-8% of American pregnant women being prescribed or using an antidepressant, according to 2020 data, and plenty more women who likely don’t seek treatment.

So, the impact of that labeling change on Feghali and her colleagues across the country isn’t minor. It also wasn’t expected.

“I was a little surprised,” she told the Post-Gazette. “I was familiar with some of the studies that mention postpartum hemorrhage and SSRIs, but I didn’t think it would actually translate to a change in labeling across the board.”

Advertise with us

SSRIs — and their sister class, SNRIs (serotonin and norepinephrine reuptake inhibitors), which include Effexor X, Cymbalta and Pristiq, among others — are known to prolong bleeding times, or make it more difficult to stop bleeding, in those who take them. That’s especially true when those patients have an NSAID (such as ibuprofen, aka Motrin and Advil) or aspirin in their systems, whether that’s for a simple headache or as a long-term regimen.

For those reasons, bleeding risks were and are noted on the labels of these medications.

She also knew that some of the studies that prove those bleeding differences, which are around 20 years old in some cases, include a discussion of (or specifically explore) postpartum hemorrhage.

As an obstetric specialist, handling moms and babies with the most risk factors, she was aware of that data, and mentally included it while caring for patients whose behavioral health during pregnancy required pharmaceutical assistance.

But now, it’s on the package insert, the little wad of thin, folded paper every patient receives along with every prescription. And Feghali and her colleagues need to decide whether to recalibrate their practices, and how to have conversations about the now-mainstream risk.

Advertise with us

Comparing the relatively small increased risk for postpartum hemorrhage when SSRIs or SNRIs are on board with knowing that one in seven American women are at risk for developing postpartum depression — and plenty more who go undiagnosed — she’s not willing to change much.

“If anything, this is more information that lends itself to provider awareness and leads potentially to a change in risk assessments at the level of different systems,” she said. “But in my mind, the findings in the studies out there are not enough that would change that risk-benefit conversation with patients.”

Her sentiments are echoed by UPMC obstetrical colleague and president of UPMC Magee-Womens Hospital Richard Beigi.

When asked if he thinks obstetricians will change recommendations to pregnant women taking SSRIs, he said, “I hope not, because behavioral health is a real problem for many pregnant persons. The important thing to understand is behavioral health treatment is very important for mothers, especially going into the delivery and the postpartum period, so I think these new findings will have to be gauged within the clinical context of the treatment of behavioral health challenges, which is not a small proportion of all the pregnant population managing these challenges, so it’s not a small issue overall.”

The potential types of changes Feghali references are in the parts of the medical care team that wouldn’t necessarily be noticeable to patients.

Advertise with us

One protocol when pregnant women are admitted to UPMC Magee-Womens Hospital — and in hospitals around the world — is a postpartum hemorrhage risk assessment. That algorithm takes age, weight, health concerns and prior history of postpartum hemorrhage into account to then classify patients as at low, moderate or high risk for postpartum hemorrhage.

Those categories lead to preparedness, such as checking the availability of cross-matched blood and having medications that halt bleeding from the uterus, known as uterotonics, readily available.

In her mind, SSRI/SNRI use leading up to delivery might someday join that calculus but, importantly, she does not think those uterotonics should automatically be utilized in these patients, as some studies suggest.

“No, that’s not usually how we approach increased risk,” she said. “Anytime we’re giving medications, specifically uterotonics, we’re always risking side effects and errors in administration that can lead to side effects,” things like fever, blood pressure increases and diarrhea, depending on the agent used. “The risk profile that is mentioned in those studies would not justify universal treatment with uterotonics in patients taking SSRIs.”

Feghali, like others in her profession, isn’t aware of any recent data that would have forced the FDA’s decision to change the labeling of these medications as they did less than two weeks ago, nor is she aware of exactly which studies the labeling refers to.

Advertise with us

At the time of publication, the FDA had not yet offered clarification publicly or to the Post-Gazette.

But Feghali also knows that while the existing data linking SSRIs and postpartum hemorrhage has been a part of her clinical judgement for some time because of her specialty and her particular interest in pharmacology, that isn’t true for everyone in her field.

And knowledge is power.

“There’s value in this data, but this is where we want to be really careful about how we implement things rather than thinking of things as being very straightforward, very black and white,” she said.

“Pregnancy is a vulnerable time. Pregnant patients are vulnerable patients at baseline because they’re really trying to balance their health with their baby’s health, and this is where messaging is really, really key in order to make sure patients make the best decisions for themselves and their families overall.”

Abby Mackey is a registered nurse, and can be reached at amackey@post-gazette.com and IG @abbymackeywrites.